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infection raise questions about the real 
pathogenic role of these viruses.
As with other polyomaviruses, 
WUPyV and KIPyV could establish 
persistent and latent infections with 
likely asymptomatic reactivations (5), 
and detection of these viruses could 
also reﬂ  ect a long-term shedding from 
previous acute episode. Recently pub-
lished studies have not shown a patho-
genic role for these new polyomavi-
ruses in respiratory tract disease (6,7); 
however, more comprehensive studies 
are needed to elucidate whether both 
KIPyV and WUPyV have any clinical 
relevance.
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Milk Replacers and 
Bovine Spongiform 
Encephalopathy in 
Calves, Japan
To the Editor: Milk replacers 
produced from a speciﬁ  c feed factory 
in Japan were suspected of being asso-
ciated with a cluster of bovine spongi-
form encephalopathy (BSE) infection 
in calves. We conducted a case–con-
trol study to test this association. 
In Japan, BSE infection has been 
conﬁ  rmed in 32 calves as of the end 
of May 2007; 13 of these calves were 
born between December 1995 and 
August 1996. One BSE-infected calf 
was born in 1992 and had an atypical 
BSE phenotype (1). Because no BSE-
infected calves were born in 1997 and 
1998, we considered that those born 
in 1995 and 1996 formed an indepen-
dent temporal cluster (Figure). Epi-
demiologic investigation showed that 
all 13 calves were fed milk replacers 
produced by a speciﬁ  c  factory.  Ten 
calves were born in Hokkaido, and 3 
were born in the Kanto region, which 
is ≈800 km away from Hokkaido.
In the case–control study, all farms 
where the 13 BSE-infected calves were 
born and raised for at least 1 year were 
deﬁ  ned as case farms. Control farms 
were deﬁ  ned as dairy farms where no 
BSE calves had been reported. Candi-
dates for control farms comprised 200 
randomly selected farms, which were 
located in 23 prefectures where the 
milk replacers were distributed. We 
used a national cattle identiﬁ  cation 
database for random selection. Vet-
erinary ofﬁ  cers from the local govern-
ment interviewed farmers in Novem-
ber and December 2006 and requested 
that they complete a questionnaire on 
farming practices in 1996, including 
herd size and use of milk replacers and 
calf concentrates. For the case farms, 
information previously obtained from 
outbreaks was used. Of the 200 po-
tential control farms, 154 farms were 
used as controls. Forty-six farms were 
excluded; 24 farmers did not respond 
or could not specify the use of milk 
replacers; and 22 farms had either 
closed or farmers did not respond for 
miscellaneous reasons.   
Among the 154 control farms, 
36 farms (23%) used the milk replac-
ers from the speciﬁ  c factory, 89 farms 
(58%) used other milk replacers, and 
29 farms (19%) did not use milk re-
placers. Since 1 case farm lacked 
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Figure. Number of cases of bovine spongiform encephalopathy by calves’ birth year, Japan. LETTERS
documented evidence about the use 
of the speciﬁ  c milk replacers, we con-
servatively assumed that 12 of 13 case 
farms used the speciﬁ  c milk replacers. 
We estimated the odds ratio for this 
risk factor by using logistic regression 
analysis. Our results indicated that the 
use of the milk replacers produced by 
the speciﬁ   c factory was associated 
with BSE infection (odds ratio [OR] 
39.3, 95% conﬁ   dence interval [CI] 
4.9–312.9, p = 0.0005). 
The milk replacers produced by 
the speciﬁ  c factory contained tallow 
that was produced at domestic render-
ing factories and imported from the 
Netherlands. Milk replacers were fed 
to calves during a relatively short pe-
riod after birth (an average of 79 and 
68 days, for case and control farms, 
respectively). If 1 production lot of 
milk replacer became accidentally 
contaminated with BSE, the exposure 
would occur in newborn calves within 
a relatively short period. This con-
tamination may explain why 11 of 13 
BSE-infected calves were born within 
a 2-month period from February 10, 
1996, to April 8, 1996. 
In Hokkaido, 9 of 10 BSE-infect-
ed calves were fed calf concentrates 
produced in the same feed factory. 
This proportion was higher than that 
of the 50 control farms in Hokkaido 
(22/50, Fisher exact test, p = 0.013). 
The calf concentrates might have be-
come contaminated with meat-and-
bone meal (MBM) because this fac-
tory used MBM for other animal feed. 
Multivariate logistic regression analy-
sis, including this factor and that for 
the speciﬁ  c milk replacers, did not in-
dicate signiﬁ  cant association between 
the speciﬁ  c calf concentrates and oc-
currence of BSE (calf concentrates: 
OR 3.2 [CI 0.8–13.0], p = 0.14; milk 
replacers: OR 21.7 [CI 2.5–192.6], 
p = 0.006). The factory that provided 
the speciﬁ  c concentrates belonged to 
a company afﬁ   liated with the com-
pany that produced the milk replacers 
in question. Given the fact that farm-
ers tend to use milk replacers and calf 
concentrates from the same company, 
association of the calf concentrates 
with the BSE infection may have been 
masked by the use of speciﬁ  c milk re-
placers. However, our study is limited 
by the small number of BSE cases and 
investigation of events that occurred 
10 years ago.   
A possible causal association be-
tween the feeding of potentially con-
taminated milk replacers to calves and 
the occurrence of BSE has been sug-
gested by several epidemiologic stud-
ies (2–5). However, no report shows 
experimental transmission of BSE by 
use of tallow or milk replacers (6). 
This lack of evidence in the literature 
may suggest that the risk of contract-
ing BSE from processed tallow or 
milk replacers is low (7). If MBM is 
excluded as a source of infection, oth-
er transmission mechanisms, such as 
the feeding of animal fat, may become 
more important. 
This research was conducted under 
a research project for using advanced 
technologies in agriculture, forestry, and 
ﬁ  sheries.  
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Control of Hepatitis 
A by Universal 
Vaccination of 
Adolescents, 
Puglia, Italy 
To the Editor: The incidence of 
hepatitis A in Italy has decreased in the 
past 2 decades because of improved 
sanitation and better living conditions 
(1). However, large outbreaks oc-
curred in the 1990s in several southern 
regions of Italy, despite lower rates of 
infection among the general popula-
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